Skin cancer research gets $1 mil.
This article was originally published in The Rose Sheet
Executive Summary
National Cancer Institute grants $1 mil. to a University of Connecticut research team to develop a topical treatment that prevents and repairs sun damage leading to skin cancer, UConn states in Nov. 8 release. Researchers say they will develop the treatment using alpha-melanocyte stimulating hormone (alpha-MSH), which increases skin pigmentation to reduce UV penetration and "repair precancerous damage that UV rays do to skin cell DNA." Melanoma, the deadliest form of skin cancer, only occurs in 8% of skin cancer cases, but "causes almost all skin cancer deaths, and its incidence is rising at the rate of 4% per year," according to the statement. "The impact of this grant is potentially tremendous," study leader Zalfa Abdel-Malek, PhD, said. The treatment would be especially beneficial to fair-skinned people and others who generally carry a high risk for skin cancer, Abdel-Malek added...
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.